Ann: Positive Results from Australian Adult Clinical Studies, page-58

@bruutz82 said:
"You can add Asthma, Pneumonia and whatever else you like in there but there are only so many doctors in Australia who will utilise the app."

Australia isn't the main target market. The US, Europe and China are the jewels in the crown.

"And even with a license charge GP's aren't going to be wasting too much of their hard earned $$ on license fees when they can alternatively utilise a stethoscope for free."

Face to face doctor visits aren't the target market. Telehealth is the one they are after, where stethoscopes don't exist.

"A hospital may utilise RAP app but has anyone actually done rough numbers on how many patients you would need to utilise RAP on to make RAP reasonably profitable?"

Hospital emergency departments will find the tech useful to prioritise lung related ailments, although once again, they aren't Resapp's main target.
Repeat after me: telehealth telehealth telehealth.